Application 219684
- Type
- ANDA
- Sponsor
- BAXTER HLTHCARE CORP
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | KETAMINE HYDROCHLORIDE | KETAMINE HYDROCHLORIDE | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | No | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A219684-001 | KETAMINE HYDROCHLORIDE | KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | 2025-09-17 | ||
| A219684-002 | KETAMINE HYDROCHLORIDE | KETAMINE HYDROCHLORIDE | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | RS | 2026-08-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A219684-001 | KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | 2025-09-17 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A219684-002 | KETAMINE HYDROCHLORIDE | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | RS | 2026-08-11 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A219684-001 | KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | 2025-09-17 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A219684-002 | KETAMINE HYDROCHLORIDE | EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | RS | 2026-08-11 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A219684-001 | KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | RS | 2025-09-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219684-001 | KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | RS | 2025-09-17 | 31067a03dcf5… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219684-001 | KETAMINE HYDROCHLORIDE | EQ 100MG BASE/10ML (EQ 10MG BASE/ML) | SOLUTION / INTRAMUSCULAR, INTRAVENOUS | 2025-09-17 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| KETAMINE HYDROCHLORIDE | KETAMINE HYDROCHLORIDE | Baxter Healthcare Corporation | 549d6ed3-3c9b-4ea2-8aaf-f61d43e04602 | 2025-06-26 | Warnings, Adverse reactions | 219684 ANDA219684 |